The vote is in: six of seven.

For weeks the honest thing to say about the July peptide meeting was "we don't know yet, and a vote wouldn't change the law overnight anyway." The meeting has now happened — July 23 and 24 — and the results are worth reporting plainly, because the headlines are already running ahead of the facts in both directions.

Here is what the FDA's Pharmacy Compounding Advisory Committee (PCAC) actually did, substance by substance.

The recorded tallies.

How we sourced these numbers, and where they disagree. The committee is 14 members, and every substance was voted as two entries — free base and acetate. The tallies above are reconciled from contemporaneous trade and national reporting. ^†Public accounts of the Epitalon vote differ: some report 7–4 with one abstention, others 7–5 with one abstention. The outcome — recommended — is not in dispute; the exact no-count is. We are leaving the discrepancy visible rather than picking the tidier number, and we will reconcile this line against the FDA's official meeting minutes and transcript when they post. If you find we have a digit wrong, tell us and we will correct it with a dated note.

That is six favorable recommendations out of seven, with only DSIP — listed in the docket under its international name, emideltide — voted down, and narrowly, 6 to 7. What makes this notable is the starting point: the FDA's own scientific briefing documents had recommended against all seven. The committee heard those documents and the public testimony and, on most of the slate, disagreed with staff. That is the system working as designed, not a rubber stamp.

Why this does not change your prescription this week.

A PCAC vote is a recommendation to the FDA, not a rule. The agency is not bound by it. Before the durable, on-the-shelf legal status of any of these peptides actually changes, the FDA has to accept the committee's input, publish a proposed rule, run a second public comment period, and then issue a final rule. Prior 503A bulks-list cycles have run roughly eight to twenty-four months end to end, and legal commentators covering this vote have said the process "may take over a year." Our working expectation is twelve to twenty-four months, with final action unlikely before late 2027 — and we will revise that publicly if the agency moves faster. Nothing about how Limitless sources or prescribes changes on the strength of a July advisory vote.

This is not a minority reading. As of August 2026, the national health-care regulatory bar has converged on it. Holland & Knight's August analysis frames the vote as "a step toward" eligibility for lawful compounding rather than the thing itself, and Sheppard Mullin's status tracker states the position in its most useful form: the six peptides are not currently listed in 21 CFR § 216.23, the FDA has issued no final determination, none of them became an FDA-approved drug because of the vote, and lawful compounding remains prohibited absent FDA acceptance plus completed proposed and final rulemaking. If you encounter a clinic page telling you these peptides are now legal, approved, or "back on the list," you can check that claim against the Code of Federal Regulations yourself — the section number is right there.

If you are a current patient, your protocol is unchanged, and any future change happens the way it always would — in a direct conversation with me, keyed to your labs and your goals, not to a news cycle.

What it means specifically for MOTS-c.

MOTS-c is worth calling out because it sits at an unusual intersection: it is a peptide the committee recommended favorably and one already in the Limitless toolkit for mitochondrial and metabolic support. A favorable recommendation doesn't manufacture human efficacy data that isn't there yet — the mechanism (AMPK activation, mitochondrial signaling) is well characterized, but large human outcome trials are still thin, and we say so. What the recommendation does do is signal that a durable, regulated 503A pathway for this molecule is more plausible than the FDA staff posture suggested a month ago. We will keep sourcing it through licensed 503A compounding pharmacies and disclosing the evidence honestly. You can read our full evidence and positioning read on the MOTS-c page.

What a patient should actually do with this.

1. Discount the loud headlines. "Peptides are legal now" is wrong in the same way "peptides are banned" was wrong. The operative legal status did not flip on July 24.
2. Keep asking where a peptide is sourced. The right answer from any clinic is a licensed 503A compounding pharmacy with per-lot testing — never a research-chemical vendor. That question matters more than the PCAC calendar.
3. Expect a slow clock. Even six favorable votes start a rulemaking process measured in years, not quarters — twelve to twenty-four months, with final action unlikely before late 2027. Be skeptical of any clinic that markets these votes as if the rule already changed — that kind of overclaim is exactly what draws FDA and FTC scrutiny.
4. Watch the dated tracker. We record every material development on the PCAC Watch page, including the FDA's formal written response when it comes and the second peptide review already signaled for early 2027.

What the coverage got right, and what it blurred.

This vote was covered nationally — by STAT, ABC News, The Hill, and the trade press. The reporting got the core facts right: the votes were narrow, the committee overruled its own scientific staff, and the recommendations are not binding. Two things deserve more emphasis than most headlines gave them.

First, the panel's composition is part of the story. Reporting has noted that a majority of the members who voted yes have professional or financial ties to the peptide industry, and that several were appointed under the current HHS leadership. That does not make the votes illegitimate — advisory committees routinely seat practicing clinicians, and expertise and interest are hard to separate. But it does mean a favorable PCAC recommendation is weaker evidence about the underlying science than a casual reader might assume. If a clinic quotes this vote to you as proof that a peptide works, that is a misuse of it. The vote was about whether pharmacies may compound these substances, not about whether they are effective.

Second, "narrow" is doing real work. A 7-to-5 recommendation with two abstentions — the MOTS-c result — is not a scientific consensus. It is a split committee. We would rather tell you that than round it up.

The question almost nobody covered: a dietary-supplement pathway.

One thread from the hearing got very little attention outside the trade press, and it may end up mattering more than the vote tallies. As NutraIngredients reported on July 27, committee discussion repeatedly circled back to a structural question: if these substances have a real constituency and a plausible safety profile but insufficient evidence for drug-level review, should some of them be sitting in the dietary-supplement framework instead of the compounding one?

It sounds like a technicality. It is not. The two frameworks are almost opposites in the ways that matter to a patient:

So a "supplement pathway" would be faster and looser, and it would be marketed to patients as a win — easier access, no prescription needed. From where I sit it is the worse outcome of the two. It would strip out the prescription requirement, the sterility standard, the per-lot testing, and the physician who is supposed to be watching what happens next. For an oral or topical substance with a benign profile, that trade might be defensible. For an injectable peptide with thin human data, it is not.

I want to be careful here: no such pathway has been proposed. This was committee discussion, not agency policy, and it may go nowhere. But it is worth flagging now because of how it will be sold if it does happen — and because the argument for physician-supervised sourcing does not get weaker if the law gets looser. It gets more important.

The bottom line.

On July 23–24, 2026, the PCAC recommended adding six of seven peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — to the 503A bulks list, and declined only DSIP. That is a genuinely favorable read from an advisory body that started from a skeptical staff brief. It is also a recommendation, not a rule: the law changes later, through FDA rulemaking, if at all. The molecules at the core of the Limitless library — tesamorelin, testosterone, tadalafil — were never part of this question to begin with. That is the whole picture, dated and unhyped.

Want the three-minute patient version? Read the patient FAQ. For the running log of every development, see the PCAC Watch tracker, and for background on how the process works, the earlier plain-language status read.